These cancers instead rely on the PARP repair pathway, making this back-up pathway a solid target for anti-cancer treatments. The key to building on this success for a wider range of cancers is ...

Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

Under the terms of the settlement, Allarity has consented, without admitting or denying the SEC’s findings, to the entry of an administrative cease-and-desist order. The settlement resolves the SEC’s ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

The trial focused on stenoparib, a novel dual PARP/Wnt pathway inhibitor, and its effectiveness in patients with platinum-resistant or refractory ovarian cancer. These patients typically have ...